Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
In the initial week of treatment, we may recommend five to seven injections, depending on the severity of your vitamin B12 insufficiency
Who Should Consider Avoiding BPC-157 Despite the overall reassuring safety profile, certain populations should strongly consider avoiding BPC-157 given the theoretical concerns about angiogenesis and cancer
i was reading this thread and it sounds like you are a few weeks ahead of me so keen to hear how you are doing and if there is in fact light at the end of the tunnel Thanks
Arrive at TRTMD prepared to live life symptom-free